IVUS Assessment of Atheroma Burden After Acute Coronary Syndrome
Launched by UNIVERSITY HOSPITAL, TOULOUSE · Apr 12, 2012
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
According to current guidelines, patients with coronary lesions with stenosis \<70% should receive optimal secondary prevention drug treatment without angioplasty, even after an acute coronary syndrome (ACS). Nevertheless, coronary angioplasty is rather frequently performed in such situations, presumably because, changes in the atherosclerotic plaque under drug treatment, have remained poorly described so far. Intravascular ultrasound (IVUS) enables a precise description of coronary atheroma, better than the one provided by coronary angiography.
The first objective is to assess by endo-cor...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients hospitalized for ACS, for whom the target lesion has less than 70% stenosis and not treated with coronary angioplasty.
- Exclusion Criteria:
- • Patients presenting with a target lesion with ≥70% stenosis ; Patients for whom the target lesion is treated with coronary angioplasty ; Interventions: A first IVUS will be performed after the acute coronary event (baseline) and will be done again one-year after to assess changes in the atherosclerotic plaques.
About University Hospital, Toulouse
The University Hospital of Toulouse is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care, the hospital integrates cutting-edge scientific inquiry with comprehensive clinical services. Its multidisciplinary team of healthcare professionals collaborates with renowned researchers to facilitate pioneering studies across various medical fields, aiming to enhance treatment options and improve patient outcomes. As a prominent institution in the region, the University Hospital of Toulouse is committed to fostering an environment of excellence in both education and research within the healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toulouse, , France
Limoges, , France
Pessac, Bordeaux Pessac, France
Patients applied
Trial Officials
Meyer Elbaz, PhD
Study Chair
University Hospital, Toulouse
Pierre Coste, PhD
Principal Investigator
University Hospital, Bordeaux
Patrice Virot, PhD
Principal Investigator
UH Limoges
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials